ASHP Midyear Spotlights New COPD Treatments

By Marcus A. BanksAfter several decades without new treatment options for chronic obstructive pulmonary disease (COPD), three new drugs gained FDA approval over the past two years: the biologics dupilumab (Dupixent, Sanofi and Regeneron) and mepolizumab (Nucala, GlaxoSmithKline) and inhaled ensifentrine (Ohtuvayre, Verona).Crystal light - stock.adobe.com“This is exciting. We’ve mostly been using the same medications to treat COPD for the last 20 or 30 years,” said Nathan Pinner